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Background: To document the effect of bivalent HPV immunisation on cervical cytology as a screening test and assess the
implications of any change, using a retrospective analysis of routinely collected data from the Scottish Cervical Screening
Programme (SCSP).
Methods: Data were extracted from the Scottish Cervical Call Recall System (SCCRS), the Scottish Population Register and
the Scottish Index of Multiple Deprivation. A total of 95 876 cytology records with 2226 linked histology records from women
born between 1 January 1988 and 30 September 1993 were assessed. Women born in or after 1990 were eligible for the national
catch-up programme of HPV immunisation. The performance of cervical cytology as a screening test was evaluated using the key
performance indicators used routinely in the English and Scottish Cervical Screening Programmes (NHSCSP and SCSP), and
related to vaccination status.
Results: Significant reductions in positive predictive value (16%) and abnormal predictive value (63%) for CIN2þ and the mean
colposcopy score (18%) were observed. A significant increase (38%) in the number of women who had to be referred to colposcopy to
detect one case of CIN2þ was shown. The negative predictive value of negative- or low-grade cytology for CIN2þ increased
significantly (12%). Sensitivity and specificity, as used by the UK cervical screening programmes, were maintained.
Conclusions: The lower incidence of disease in vaccinated women alters the key performance indicators of cervical cytology used
to monitor the quality of the screening programme. These findings have implications for screening, colposcopy referral criteria,
colposcopy practice and histology reporting.
The UK cervical screening programme is a success and is estimated
to have prevented the deaths from cervical cancer of 1 in 65
women born since 1950 (Peto et al, 2004). This success can be
attributed to adherence to national protocols for regular screening
and a strong commitment to regular quality assurance and
monitoring. The clinical performance of any screening test is
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crucial and will be influenced not only by fundamental attributes of
the test but also by the prevalence of the target disease in the
population. This is particularly the case for tests that require
subjective interpretation. The primary modality of screening
in the UK is liquid-based cytology although primary screening
using HPV testing is being piloted at six sites in England
(http://www.cancerscreening.nhs.uk/cervical/hpv-primary-screen-
ing.html). In Scotland, cytological primary screening is supple-
mented by image assisted screening (ThinPrep Imaging System,
HOLOGIC Inc, Marlborough, MA, USA.
The advent of immunisation against the two most common
high-risk types of HPV (HPV16 and 18) is beginning to alter
profoundly the prevalence of HPV16 and 18, as well as HPV 31, 33
and 45, in the population (Kavanagh et al, 2014; Pollock et al, 2014;
Cameron et al, 2016). Immunisation with the bivalent vaccine
began in Scotland in September 2008, with routine immunisation
of girls aged 12–13 years in school and a catch-up programme
for girls up to the age of 18 years. As a result, the amount of
cervical intraepithelial neoplasia (CIN), the precursor of invasive
cervical cancer, is also changing in young women attending
for cervical screening. Scotland begins cervical screening at age
20 years, so girls immunised as part of catch-up have been screened
since 2010. Significant reductions in type specific HPV infection
and all grades of CIN, more pronounced with high-grade CIN,
have already been demonstrated in Scotland and elsewhere
(Kavanagh et al, 2014; Pollock et al, 2014; Drolet et al, 2015).
Much effort is invested in monitoring the effectiveness of
cytology to detect high-grade cervical intraepithelial neoplasia
(CIN) (ABC, 2013). Various measures have been devised to
quantify this for various grades of cytology, including the positive
predictive value (PPV) of high-grade dyskaryosis to detect high-
grade CIN (HGCIN) and the ability of persistent low-grade
cytology to predict HGCIN (abnormal predictive value, APV).
Such quality monitoring is particularly relevant given predictions
that the performance of cervical cytology may deteriorate as a
consequence of immunisation. A reduction in disease in a screened
population will directly reduce the PPV of any screening test
(Franco et al, 2006). In cervical screening, the relative proportions
of high- to low-grade disease influence the PPV for high-grade
disease, the target of screening. With cytology as a screening test,
this effect may be exaggerated by reader fatigue, with the possibility
of missing rare positive events and of overcalling clinically
insignificant reactive atypia. These forecasts are theoretical as no
data from screening programmes have been published, given the
time between vaccination and entry into cervical screening and the
challenges of linking data between immunisation and screening
databases robustly.
The IT system (Scottish Cervical Call-Recall System, SCCRS)
which manages the cervical screening call and recall programme in
Scotland holds cytology results, associated histology reports and
also immunisation status including the number of doses. Scotland
is well placed to assess the impact of immunisation on the
performance of cervical cytology. In this paper, we consider
the impact of immunisation on the performance of cytology for the
detection of CIN.
MATERIALS AND METHODS
Scottish cervical screening programme (SCSP). Cervical screen-
ing starts at age 20 years in Scotland, with women being called
within 4–6 weeks of their 20th birthday. All of Scotland uses
Thinprep liquid based cytology with image assisted screening
(ThinPrep Imaging System, HOLOGIC Inc). A total of eight NHS
cytology laboratories serve the programme and process B400 000
samples a year (http://www.sccrs.scot.nhs.uk/lab.html). Cytology
and histology classification is performed according to British
Association for Cytology and NHS Cervical Screening Programme
(NHSCSP) criteria (Denton et al, 2008; NHSCSP, 2010). A
comparison between the various reporting systems in use is given
in Figure 1.
Referral for colposcopy is made after one instance of high-grade
disease or borderline, query high-grade (ASC-H) and for persistent
low-grade disease. Persistent low-grade disease is defined as two
instances of low-grade dyskaryosis or three instances of borderline
change during an episode of abnormal follow-up, or three
abnormal smears in the last 10 years. In addition, referral for
colposcopy is made following three consecutive unsatisfactory
smears (SCSP, 2013).
Selection of analysis cohort. The screening records of women
resident in Scotland and born between 1 January 1990 and
30 September 1993 who had cytology tests taken after the age of
20 years and before age 21 years, in their first year of eligibility for
screening, were examined in this analysis. Data were extracted
from SCCRS at the end of September 2014, giving a minimum of
12 months follow-up for each woman. The following data were
extracted:
 Result of cytology tests taken in the first year of screening
 Histology results taken at colposcopy as a consequence of the
cytology result
 Immunisation status by number of doses received (0, 1, 2 or 3
doses)
 Year of birth
 Postcode of residence
For most women, the results corresponded to their first smear
or first colposcopy examination. For the relatively few women with
more than one smear or biopsy the most severe result was used for
analysis.
The extract criteria were chosen to obviate bias due to age at
time of screening, and due to opportunity for disease detection.
NHSCSP Two-tier The Bethesda system
ASC-US/ASC-H/AGUS
Borderline squamous and
glandular changes without
HPV
HPV changes (koilocytosis)
+/– low grade dyskaryosis
High grade dyskaryosis
(moderate)
High grade dyskaryosis
(severe)
High grade dyskaryosis/
invasive
Glandular neoplasia
High-
grade
Low-
grade LSIL
HSIL
Cancer
AGC favour neoplasia
AIS, adenocarcinoma
Figure 1. Cytology classification according to British Association for
Cytology (BAC) and NHS Cervical Screening Programme (NHSCSP)
criteria (Denton et al, 2008).
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The records extracted were compared with the population register
to eliminate women who were not resident in Scotland at the time
of immunisation. Duplicate records were identified and the
cytology and histology results amalgamated into a single patient
record. Following these two steps, the postcode of residence was
used to derive the SIMD quintile and rurality index. The records
were anonymised with preservation of linkage between immunisa-
tion, cytology, and histology where appropriate. Caldicott
Guardian approval was obtained for the use of patient-identifiable
data.
Statistical methods
Impact of immunisation on cytological abnormalities and on
histological diagnosis. In order to be able to measure the
performance of cytology and place it in context, the impact of
immunisation on cytological and histological abnormalities was
assessed. The cytology result was recorded as Inadequate, Negative
(no evidence of disease), Borderline (including borderline gland-
ular changes), and Low-grade, Moderate or Severe dyskaryosis
(including glandular abnormalities). Histology was coded as
Normal (no CIN detected), CIN1, CIN2, and CIN3þ (CIN 3 or
cancer). The associations between the outcomes of colposcopy and
cytology and the demographic variables were estimated using
multinomial logistic regression models. Odds ratios (ORs) for the
various response levels compared with the baseline or normal
levels are reported with 95% confidence intervals (CIs). Univariate
and multivariable models were used. In addition to the number of
doses of vaccine, we investigated birth cohort, Scottish Index of
Multiple Deprivation, (with level 1 corresponding to the most
deprived), and an Urban Rural indicator, derived from the Scottish
Government 8 level indicator and with three levels: Urban,
Accessible Rural (30–60min drive to a settlement of 10 000 or
more), and Remote Rural (460-min drive to a settlement of 10 000
or more). Two-level interactions were investigated using a
Bonferroni correction to the P-value for multiple testing.
Linked histology records and cytology results were tabulated
and correlated with the number of doses of vaccine administered.
Comparison of the measures of test performance between fully
vaccinated and unvaccinated individuals was conducted using a w2-
test of association with a Bonferroni correction used to account for
multiplicity of testing based on the different measures and the two
end points, CIN2þ and CIN3þ . Confidence intervals for
binomial proportions were calculated using Wilson’s method. In
a sensitivity analysis this comparison was adjusted for cohort as the
1988 and 1989 cohorts are unimmunised and only the later ones
have some fully immunised individuals. Logistic regression was
used here with analysis of deviance tests.
Impact of immunisation on performance of cytology. In women
who had a satisfactory colposcopic examination the following
measures were calculated according to the formulae in the UK
Cervical Screening Programme guidance ‘Achievable Benchmarks
in Cytology’, version 3 (ABC, 2013) (Figure 2). Both CIN2þ and
CIN3þ were used as end points:
 Sensitivity of high-grade dyskaryosis for CIN2þ and CIN3þ ;
 Specificity of negative, borderline or low-grade dyskaryosis
for absence of high-grade CIN;
 Positive predictive value of high-grade dyskaryosis for HGCIN;
 Abnormal predictive value of persistent low-grade dyskaryosis
and/or borderline changes for HGCIN;
 Referral value, which is the number of women who are referred
to colposcopy to detect one case of HGCIN;
 Total predictive value of any cytological abnormality for
HGCIN;
 Negative predictive value of low-grade or negative cytology for
HGCIN;
 Mean CIN Score—the (weighted) average amount of disease
per case seen at colposcopy (MCS).
RESULTS
Data extract. The final data set contained a total of 95 876
cytology records from women aged between 20 years and 20 years
and 364 days, of whom 2226 had attended colposcopy. These
women with both cytology and histology records were used for the
analysis of cytology performance. A total of 34 161 (35.6%) women
had received three doses of vaccine (complete schedule of
immunisation in the catch-up cohorts), whereas 57 140 (59.6%)
were unvaccinated. Only 1475 (1.5%) and 3100 (3.2%) records
were associated with women who had received one and two doses
of vaccine, respectively (Table 1).
Impact of immunisation on cytological abnormalities. Com-
plete immunisation with three doses was associated with a highly
significant (Po0.001) reduction in all grades of cytological
abnormality (Table 2). The reduction in high-grade dyskaryosis
was greater than that observed for low-grade abnormalities. When
compared with fully vaccinated women, unvaccinated women had
an odds ratio of severe dyskaryosis of 2.95 (95% CI 2.17–4.02), for
moderate dyskaryosis of 2.43 (95% CI 1.94–3.05), for low-grade
dyskaryosis of 1.38 (95% CI 1.26–1.51), and for borderline changes
of 1.27 (95% CI 1.19–1.35). Partial immunisation with two doses
was also associated with a reduction in low-grade dyskaryosis
(OR 1.13, 95% CI 0.95–1.34) compared with unvaccinated
(OR 1.38, 95% CI 1.26–1.51) but this was not statistically
significant. Immunisation with one dose of vaccine was not
associated with a reduction of abnormal cytology when compared
with no immunisation.
The proportions of women with the different grades of
abnormal cytology varied by birth cohort (Po0.001). However,
once adjusted for number of doses of the vaccine, only the
reduction in borderline changes in the 1993 cohort remained
significant. There are trends associated with deprivation
(Po0.001) with higher odds of disease for all outcomes among
the most deprived individuals (Table 2).
Cytology result
Low-grade cytology
(boderline/mild)
High-grade cytology
(moderate or worse) c
a
Negative HPV
only
CIN1
Histology result
CIN2, CIN3, invasive cancer
CGIN/adenocarcinoma in situ
b
d
Figure 2. Formulae used for derivation of predictive values.
Positive predictive value¼d/(cþd)
Abnormal predictive value¼b /(aþb)
Total predictive value (TPV)¼ (bþd) / (aþbþ cþd)
Negative predictive value¼ a/(aþb)
RV ¼ 1/TPV.
Abbreviations: CGIN¼ cervical glandular intraepithelial neoplasia;
CIN¼ cervical intraepithelial neoplasia.
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Impact of immunisation on performance of cytology. In women
with a satisfactory colposcopy (n¼ 2226), the sensitivity ofXhigh-
grade dyskaryosis for CIN2þ and the specificity of plow-grade
dyskaryosis for o¼CIN1 was slightly higher in fully immunised
vs non-immunised women although these differences were not
significant (Tables 3a and 3b).
The PPVs of Xhigh-grade dyskaryosis for both CIN2þ and
CIN3þ reduced in fully immunised women by 16% (P¼ 0.002)
and 14% (P¼ 0.25, NS), respectively. The NPV of plow-grade
dyskaryosis was higher in immunised women than in non-
immunised women for both CIN2þ (P¼ 0.002) and CIN3þ
(P¼ 0.033 (NS)). The APV of low-grade and borderline changes
for CIN2þ decreased in fully immunised women for CIN2þ by
63% (P¼ 0.002) and for CIN3þ by 97% (P¼ 0.049 (NS)). The
number of women who had to be referred to colposcopy to detect
one case of high-grade disease (referral value) was significantly
increased for both CIN2þ and CIN3þ in fully immunised
women (Po0.001 and P¼ 0.005, respectively). There was a
corresponding significant decrease (Po0.0001) in the average
amount of disease per case seen at colposcopy (MCS) in fully
immunised women (MCS¼ 1.23 (s.d.¼ 1.04)) compared with
unimmunised women (MCS¼ 1.46 (s.d.¼ 1.07)). In a sensitivity
analysis the comparison of fully immunised women with
unimmunised women was adjusted for cohort. There was no
evidence of a temporal trend associated with cohort and the
conclusions were unaffected (data not shown).
DISCUSSION
Scotland is almost uniquely placed to determine the impact of
immunisation on the performance of cytology screening in young
women using national data sets, which can be linked effectively.
The results show preservation of sensitivity of high-grade cytology
for CIN2þ and specificity of negative or low-grade cytology for
the absence of CIN2þ , yet a deterioration overall in the predictive
value of cytology for the detection of CIN2þ . These findings
confirm the expectation of Franco et al (2006) who predicted a
reduction in the overall performance of cytology as a consequence
of vaccination. In their 2006 paper, Franco used estimates of
sensitivity (51%) and specificity (98%) based on the correlation of
HSIL with CIN2þ taken from Nanda et al (2000). In their 2009
modelling, Franco et al, 2009 used a sensitivity of 70% and
specificity of 98%, similar to those achieved by the SCSP.
Furthermore, these authors examined the effect of variations of
sensitivity and specificity on the predictive value at various levels of
disease prevalence. When the sensitivity and specificity are
maintained, PPV drops sharply and progressively at disease
prevalence of o10%. As sensitivity falls, PPV declines even
further. The prevalence of high-grade disease in the fully
immunised cohorts is significantly lower in younger women, and
we expect it to fall still further when the routinely immunised
women enter the screening programmes in the UK from
September 2015. Positive predictive value is dependent on disease
prevalence, but cytology is a subjective technique, relying on
pattern recognition. Thus, the effect on PPV may be exaggerated
with a knock on effect for colposcopy by failing to identify a
population with sufficiently high-risk to warrant further
intervention.
The significant reduction in PPV of high-grade dyskaryosis for
the detection of CIN2þ contrasts with the maintained PPV for
CIN3þ . This may reflect the small numbers of CIN3þ cases in
the fully immunised women compared with CIN2þ cases, and
hence wider confidence limits. Other reasons for the difference
between the outcomes for CIN2þ and CIN3þ include difficulty
in the interpretation of cytology and difficulty in correctly
distinguishing CIN2 from reactive metaplasia on histology in
immunised women. The cytological features usually interpreted as
dyskaryosis may have different significance in immunised than
non-immunised women, being more likely to represent reactive
changes and metaplasia than significant disease. The diagnosis of
CIN2 is less robust than CIN3, with a greater possibility of over
diagnosing reactive viral changes (Robertson et al, 1989; Mesher
et al, 2015). The difficulty in interpreting correctly the cytology and
histology may be a result of the changing HPV distribution in
immunised women. Most of the high-grade disease observed in the
UK in non-immunised women has been driven by HPV 16 and 18
(Mesher et al, 2015). HPV 16 particularly is known to have a
shorter natural history in the development of CIN3. Lesions related
to non-vaccine types may be detected at an earlier stage of
development than hitherto, when they are smaller and have less
Table 1. Number of women born between 1 January 1988 and 30 September 1993 who attended for cervical screening within 1
year of becoming 20 years, by year of birth: outcome of cytology, outcome of any colposcopy examination and number of doses
of HPV vaccine received
Year of Birth 1988 1989 1990 1991 1992 1993 Total
Total number 17 139 16451 17040 17 125 16 382 11739 95 876
Cytology
Normal 82.1 82.6 81.6 83.5 83.6 84.5 82.9
Borderline 10.6 11.1 12.3 11.4 10.2 7.5 10.7
Low-grade dyskaryosis 5.3 4.7 4.5 4.0 5.3 7.0 5.0
High-grade dyskaryosis (Moderate) 1.2 1.0 1.1 0.8 0.6 0.7 0.9
High-grade dyskaryosis (severe) or worse 0.7 0.6 0.5 0.4 0.3 0.4 0.5
Colposcopy attendance (%) with outcome
No colposcopy 97.09 97.22 97.32 97.83 98.38 98.50 97.68
Colposcopy 2.91 2.78 2.68 2.17 1.62 1.50 2.32
Normal 0.78 0.72 0.70 0.57 0.41 0.32 0.60
CIN1 0.67 0.81 0.70 0.61 0.48 0.45 0.62
CIN2 0.86 0.69 0.68 0.55 0.42 0.48 0.61
CIN3 0.61 0.57 0.59 0.44 0.32 0.25 0.47
Immunisation
Unimmunised 99.94 99.68 80.32 27.45 17.49 20.10 59.60
Partially immunised 1 dose 0.02 0.05 1.29 3.09 2.53 2.56 1.54
Partially immunised 2 doses 0.01 0.09 2.77 6.80 5.20 5.07 3.23
Fully immunised 3 doses 0.03 0.18 15.62 62.65 74.78 72.28 35.63
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼human papilloma virus.
HPV immunisation and cervical screening BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.474 585
specific features. Further, it may be that the non-vaccine related
types have different cytological presentations (Bosch et al, 2008;
Thomsen et al, 2015).
The reduction in the APV is also clinically important in cytology
based screening, as current management protocols for low-grade
cytology are centred on the likelihood of high-grade CIN being
present (NHSCSP20, 2010). This reduction was only significant using
CIN2þ as an outcome despite a much greater percentage reduction
for CIN3þ (54% ) than for CIN2þ (39%). The lack of significance
at the CIN3þ level could be influenced by the small number of cases
in this young age group. The higher negative predictive value (NPV)
of low-grade cytology in immunised women is in keeping with the
reduced APV. For CIN3þ , this offers considerable reassurance as
o1 in 20 immunised women with persistent low-grade abnormalities
will have CIN3þ .
The strengths of this study include the use of routinely collected
data from a nationally organised cervical screening programme
that uses a single information system, SCCRS. The information in
SCCRS is scrutinised regularly as it is used to monitor the
performance and quality of the programme. The HPV immunisa-
tion programme is also organised at a population level, with high
uptake and direct linkage to the cervical screening data. The
histological diagnoses of women referred for colposcopy and who
had a biopsy are comparable to those already reported from
Scotland (Pollock et al, 2014).
A weakness of the study is that the immunised women attending
for screening were vaccinated as part of the catch-up programme,
and some will have been sexually active before immunisation
(Kavanagh et al, 2014; Pollock et al, 2014). This would reduce the
effectiveness of immunisation, and also influence the effect of
immunisation on cytology performance. The data presented in this
paper may therefore underestimate the true effect of immunisation
on cytology performance in women immunised as part of the
routine programme. In addition, the true immunisation status is
only known for women immunised as part of the national
programme. Women moving into Scotland and those immunised
in the private sector are recorded on SCCRS as unvaccinated.
Although relatively few women come into either of these
categories, this also leads to a slight underestimate of the true
effect of immunisation.
The measures of cytology performance may be confounded by
colposcopy performance and disease ascertainment, and by non-
attendance at colposcopy. Knowledge of referral cytology is
recognised as influencing the colposcopic impression (Shafi et al,
1993). Given that colposcopy performance relies on pattern
recognition by the practitioner, unfamiliarity with this new referral
population may result in the colposcopist missing disease or,
alternatively, increasing the number of interventions, biopsies or
treatment with negative histology. This may not be a significant
problem at present because there are relatively few fully immunised
women in the screening programme, but it will be become
increasingly important. This will have to be addressed through
colposcopy training and quality assurance.
The key performance indicators have been calculated using known
histology outcomes only. An alternative methodology is to presume
that all women who attend colposcopy and are not biopsied, and all
those who do not attend colposcopy, do not have disease (called
‘predictive value of referral’). Although the use of only histological
outcomes will overestimate the predictive values, the use of the
referral population, irrespective of attendance, will underestimate
Table 2. Adjusted multivariate (OR) and 95% confidence limits (LCL lower, UCL upper) for the cytology outcomes of borderline,
low-, moderate- and severe-grade dyskaryosis
Low grade High-grade
Borderline Low-grade dyskaryosis Moderate dyskaryosis XSevere Dyskaryosis
No. of
women
n % OR (CI) n % OR (CI) n % OR (CI) n % OR (CI)
Year of birth
1988 17139 1823 10.64 1.23 (1.12, 1.36) 910 5.31 0.61 (0.55, 0.69) 206 1.20 0.99 (0.74, 1.33) 121 0.71 1.00 (0.68, 1.48)
1989 16451 1830 11.12 1.28 (1.16, 1.41) 775 4.71 0.54 (0.48, 0.61) 164 1.00 0.82 (0.61, 1.11) 93 0.57 0.08 (0.54, 1.20)
1990 17040 2098 12.31 1.49 (1.36, 1.63) 768 4.51 0.55 (0.49, 0.62) 179 1.05 0.98 (0.73, 1.30) 88 0.52 0.84 (0.57, 1.24)
1991 17125 1945 11.36 1.50 (1.38, 1.63) 681 3.98 0.56 (0.50, 0.62) 132 0.77 1.02 (0.77, 1.34) 69 0.40 0.99 (0.68, 1.46)
1992 16382 1672 10.21 1.39 (1.27, 1.51) 862 5.26 0.77 (0.69, 0.84) 91 0.56 0.82 (0.61, 1.11) 55 0.34 0.95 (0.64, 1.42)
1993 11739 877 7.47 1.00 822 7.00 1.00 82 0.70 1.00 43 0.37 1.00
SIMD
1 Most
deprived
21468 2459 11.45 1.13 (1.06, 1.20) 1168 5.44 1.16 (1.06, 1.27) 261 1.22 1.81 (1.46, 2.25) 146 0.68 2.21 (1.62, 3.03)
2 20 211 2156 10.67 1.05 (0.98, 1.12) 1035 5.12 1.08 (0.99, 1.19) 205 1.01 1.52 (1.21, 1.9) 133 0.66 2.13 (1.55, 2.92)
3 18 743 1994 10.64 1.05 (0.98, 1.12) 904 4.82 1.02 (0.92, 1.12) 154 0.82 1.21 (0.95, 1.55) 66 0.35 1.10 (0.76, 1.58)
4 16 957 1730 10.20 1.00 (0.93, 1.07) 827 4.88 1.03 (0.93, 1.13) 114 0.67 1 (0.78, 1.3) 70 0.41 1.31 (0.92, 1.88)
5 Least
deprived
18497 1906 10.30 1.00 884 4.78 1.00 120 0.65 1.00 54 0.29 1.00
Dose of vaccine
0 57140 6516 11.40 1.27 (1.19, 1.35) 2938 5.14 1.38 (1.26, 1.51) 644 1.13 2.43 (1.94, 3.05) 363 0.64 2.95 (2.17, 4.02)
1 1475 179 12.14 1.33 (1.13, 1.56) 89 6.03 1.38 (1.10, 1.72) 14 0.95 1.92 (1.11, 3.34) 11 0.75 3.07 (1.63, 5.80)
2 3100 353 11.39 1.22 (1.08, 1.37) 155 5.00 1.13 (0.95, 1.34) 35 1.13 2.28 (1.57, 3.3) 16 0.52 2.13 (1.24, 3.65)
3 34 161 3197 9.36 1.00 1636 4.79 1.00 161 0.47 1.00 79 0.23 1.00
Urban rural
Urban 88904 9589 10.79 1.21 (1.06, 1.39) 4460 5.02 1.07 (0.89, 1.29) 781 0.88 0.79 (0.54, 1.16) 419 0.47 0.51 (0.33, 0.77)
Accessible
rural
4277 412 9.63 1.10 (0.93, 1.3) 231 5.40 1.18 (0.94, 1.47) 44 1.03 1.03 (0.64, 1.66) 26 0.61 0.75 (0.43, 1.32)
Very
remote
rural
2695 244 9.05 1.00 127 4.71 1.00 29 1.08 1.00 24 0.89 1.00
Abbreviations: CI¼ confidence interval; OR¼odds ratio; SIMD¼ scottish index of multiple deprivation. n is the number of women with the event % is the percentage of women with the event.
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predictive values as some of the non-attenders will have significant
disease. Referral urgency is graduated according to the cytology and it
is possible, for example, that women with persistent low-grade
disease, who wait longer for colposcopy, are less likely to attend than
women with high-grade disease; similar biases may exist for taking
coloposcopic biopsies. It is not possible to account for these factors
with the data available in SCCRS but ongoing studies using the
national clinical colposcopy database will address this issue.
The findings have implications for colposcopy, for cervical
cytology, and for histology reporting. There are clear implications
for colposcopy services. The prevalence of significant disease in
immunised women seen at colposcopy will reduce and the number
of women who need to be referred to detect one case of CIN2þ
will increase significantly. At the level of CIN3þ , 38% (CIN2þ ,
35%) more immunised women than non-immunised women have
to be referred following abnormal cytology to detect one case. The
criteria for referral for colposcopy need revision for immunised
women with persistent low-grade disease to avoid over
investigation. Colposcopy with or without associated diagnostic
and therapeutic interventions brings its own physical and
psychological effects (Sharp et al, 2009).
The changing environment in which cytology is practiced is
having an adverse effect on its utility as a screening test.
Performance is likely to reduce further as the proportion of
immunised women in the screened population rises, particularly in
routinely immunised women, where a greater reduction in HPV
prevalence and associated disease is anticipated. This reduction in
performance will be accentuated if the sensitivity of high-grade
cytology for CIN2þ declines. There will come a point where the
balance of benefit and harm reverses, and cytology will no longer
be the screening test of choice. With regards to histology, cervical
biopsies from immunised women may be more difficult to
interpret, and adjunctive tests may need to be used for accurate
classification (Galgano et al, 2010).
Testing for the presence of high-risk HPV is the obvious
alternative to cytology as a screening test, although we
Table 3a. Sensitivity, specificity, PPV, NPV, APV, TPV and RV of cytology for colposcopy outcomes (CIN2þ ) among women
attending for a colposcopy within 12 months of their first invitation for screening
Measure Vaccination N R Estimate (95% CI) P-value
Sensitivity high-grade dyskaryosis CIN2þ Unimmunised 807 604 74.85 (71.74, 77.72) 0.793
Fully immunised 176 134 76.14 (69.32, 81.83)
Specificity Neg/Border/LG CIN2þ Unimmunised 815 630 77.30 (74.30, 80.04) 0.950
Fully immunised 303 233 76.90 (71.83, 81.29)
PPV of high-grade dyskaryosis for CIN2þ Unimmunised 789 604 76.55 (73.47, 79.38) 0.002
Fully immunised 204 134 65.69 (58.94, 71.86)
NPV Neg/Border/LG for CIN2þ Unimmunised 833 630 75.63 (72.60, 78.42) 0.002
Fully immunised 275 233 84.73 (80.00, 88.50)
APV of Bl/LG for CIN2þ Unimmunised 759 179 23.58 (20.70, 26.73) 0.003
Fully immunised 256 37 14.45 (10.67, 19.29)
TPV of all colp for CIN2þ Unimmunised 1622 807 49.75 (47.32, 52.18) 0.000
Fully immunised 479 176 36.74 (32.55, 41.15)
RV of all colp for CIN2þ Unimmunised 1622 807 2.01 (1.92, 2.11) 0.000
Fully immunised 479 176 2.72 (2.43, 3.07)
Abbrevaitions: APV¼ abnormal predictive value; CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; colp¼ colposcopy; NPV¼ negative predictive value; PPV¼positive predictive
value; RV¼ referral value; TPV¼ total predictive value.
Table 3b. Sensitivity, specificity, PPV, NPV, APV, TPV and RV of cytology for colposcopy outcomes (CIN3þ ) among women
attending for a colposcopy within 12 months of their first invitation for screening
Measure Vaccination N R Estimate (95% CI) P-value
Sensitivity high-grade dyskaryosis CIN3þ Unimmunised 351 288 82.05 (77.70, 85.71) 0.427
Fully immunised 75 65 86.67 (77.17, 92.59)
Specificity Neg/Border/LG CIN3þ Unimmunised 1271 770 60.58 (57.87, 63.23) 0.081
Fully immunised 404 265 65.59 (60.83, 70.06)
PPV of high-grade dyskaryosis for CIN3þ Unimmunised 789 288 36.50 (33.22, 39.92) 0.249
Fully immunised 204 65 31.86 (25.85, 38.54)
NPV Neg/Border/LG for CIN3þ Unimmunised 833 770 92.44 (90.44, 94.04) 0.033
Fully immunised 275 265 96.36 (93.44, 98.01)
APV of Bl/LG for CIN3þ Unimmunised 759 51 6.72 (5.15, 8.73) 0.049
Fully immunised 256 8 3.13 (1.59, 6.04)
TPV of all colp for CIN3þ Unimmunised 1622 351 21.64 (19.70, 23.71) 0.005
Fully immunised 479 75 15.66 (12.68, 19.18)
RV of all colp for CIN3þ Unimmunised 1622 351 4.62 (4.22, 5.08) 0.005
Fully immunised 479 75 6.39 (5.21, 7.89)
Abbrevaitions: APV¼ abnormal predictive value; CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia; colp¼ colposcopy; NPV¼ negative predictive value; PPV¼positive predictive
value; RV¼ referral value; TPV¼ total predictive value.
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acknowledge that the performance of HPV-based primary screen-
ing has been assessed almost entirely in unimmunised women to
date (Dijkstra et al, 2014; Ronco et al, 2014). Consequently,
endeavours to assess the impact of immunisation on HPV primary
screening are underway in Scotland (Bhatia et al, 2014;
Cruickshank et al, 2014). Women positive for high-risk HPV are
likely have a much higher prevalence of high-grade disease than
the current primary screening population. In these circumstances,
cytology could serve as an effective triage test (Franco et al, 2009;
Rijkart et al, 2012). Our results should be generalisable to other
populations with high vaccine coverage and organised screening.
The effect of cytology performance is likely to be less noticeable in
populations with low immunisation rates, but may be relevant to
forward planning if uptake is expected to increase.
In conclusion, the performance of cervical cytology as a
screening test is adversely affected by immunisation, particularly
the ability of low-grade cytology to predict clinically significant
disease, with consequences for referral criteria and colposcopy
practice. Implications for colposcopy services include the challenge
of managing a higher proportion of referred women who have
no (or clinically insignificant) disease. Continued monitoring of
cervical screening performance in immunised women and the
assessment of new models of screening (e.g. HPV testing) more
adapted to the immunisation era are essential so that the quality of
what is arguably the most successful cancer screening programme
to date can be maintained.
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